Plain-English translation of NCT06888960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of immune therapy designed to help people with autoimmune diseases that haven't responded to standard treatments. works by helping your immune system's T cells attack the B cells that are causing your disease. Because this medication acts similarly to CAR-T therapy, researchers are being very careful to monitor for side effects, especially at the start of treatment.
Many people with autoimmune diseases like lupus, myositis, scleroderma, or rheumatoid arthritis don't improve enough with current medications. This trial is exploring whether a newer type of immune therapy could help patients whose diseases have become resistant to standard treatments.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (injection into your vein) at the study clinic. The trial uses a careful dose-escalation approach, meaning you'll first receive a small priming dose to help your body adjust, followed by therapeutic doses. The study will enroll 9 to 18 patients total across three dose groups, and you'll be monitored closely for safety and how your disease responds to the treatment.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China